https://www.thebodypro.com/category/adverse-events-comorbidities-hiv

Adverse Events, Comorbidities, and HIV

The Latest

New Professional Resources for Providers to Address HIV/HCV Coinfection Img
Hepatitis C

New Professional Resources for Providers to Address HIV/HCV Coinfection

Several new HIV/HCV coinfection resources for the HIV workforce were recently released by partners of the U.S. Department of Health and Human Services. Here's the department's quick roundup.

Promo Image
News

This Week in HIV Research: Check Your Frailty

The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.

Doctor looking at brain scan
Neurocognitive

Six Things Providers Should Know About HIV-Associated Neurocognitive Disorders

HIV-associated neurocognitive disorders, including dementia, may be well-documented issues, but they're still being understood. New research answers some questions providers may have about HIV's impact on the brain.

Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

Ellen Eaton, M.D. (right), and Kelsie Dodson.
News

Studying HIV and STI Testing Preferences in Men Who Have Sex With Men

Our series on mentor-mentee researchers continues with Ellen Eaton, M.D., and Kelsie Dodson, with the University of Alabama at Birmingham.

Promo Image
News

This Week in HIV Research: Do We Need New Statin Guidelines?

Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.

Hep C and Drug Abuse Often Go Hand in Hand, but Screening for Infection Lags Img
Hepatitis C

Hep C and Drug Abuse Often Go Hand in Hand, but Screening for Infection Lags

The number of people who inject drugs has soared, yet many drug patients are not checked for the virus that can damage the liver.

Dual Maintenance Therapy With Dolutegravir + Rilpivirine Img
News Analysis

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

Integrase Inhibitors and Weight Gain: A Top HIV Clinical Development of 2018 Img

Integrase Inhibitors and Weight Gain: A Top HIV Clinical Development of 2018

Integrase inhibitors have revolutionized HIV treatment, as a glance at HIV treatment guidelines over the past few years makes clear. And with good reason: They're well tolerated, have a high barrier to resistance, and are potent as all get out. But t...

Abacavir, Platelets, and a Cardiovascular Verdict: A Top HIV Clinical Development of 2018 Img
Cardiovascular

Abacavir, Platelets, and a Cardiovascular Verdict: A Top HIV Clinical Development of 2018

Debates about the role of abacavir (Ziagen, ABC) in the development of cardiovascular disease in persons living with HIV have raged for over a decade, and a kind of stalemate has been achieved between those who are and are not convinced of a link. Wh...